Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Obstetrics & Gynecology 1992;79:511-514
© 1992 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GROVER, S.
Right arrow Articles by KOH, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GROVER, S.
Right arrow Articles by KOH, H.

Factors Influencing Serum CA 125 Levels in Normal Women

SONIA GROVER, MBBS, MICHAEL A. QUINN, MB, ChB, PRUE WEIDEMAN, RN, RM and HOON KOH, BSc(Hons)

From the Department of Obstetrics and Gynecology, the Oncology Unit, and the Department of Immunology/Hematology, Melbourne University, Royal Women's Hospital, Carlton, Australia

Abstract

Serum CA 125 levels were studied in 2544 healthy women. Menopausal status and a history of hysterectomy were both highly significant influences on the CA 125 level (P <.0001 for both factors). A history of hormone replacement therapy was also highly significant in reducing CA 125 levels (P =.002) in postmenopausal women. Other factors such as parity, history of unilateral oophorectomy or oral contraceptive usage, or family history of ovarian cancer were not significant influences when analysis of covariance was performed. When premenopausal women were assessed separately, age was significant (P =.04). The number of years since menopause did not influence CA 125 levels. Both hysterectomy and menopausal status have a clear effect on serum CA 125 levels and must be considered if serum CA 125 is to be used as a screening test.




This article has been cited by other articles:


Home page
Hum ReprodHome page
G. Chene, F. Penault-Llorca, G. Le Bouedec, F. Mishellany, M.M. Dauplat, P. Jaffeux, B. Aublet-Cuvelier, J.L. Pouly, P. Dechelotte, and J. Dauplat
Ovarian epithelial dysplasia after ovulation induction: time and dose effects
Hum. Reprod., September 29, 2008; (2008) den358v1.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
D. K. Pauler, U. Menon, M. McIntosh, H. L. Symecko, S. J. Skates, and I. J. Jacobs
Factors Influencing Serum CA125II Levels in Healthy Postmenopausal Women
Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 489 - 493.
[Abstract] [Full Text]


Home page
Clin. Chem.Home page
H. A. Fritsche and R. C. Bast
CA 125 in Ovarian Cancer: Advances and Controversy
Clin. Chem., July 1, 1998; 44(7): 1379 - 1380.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Obstetricians and Gynecologists.